|
Sep 6
|
Google's investment arm leads $210M raise for biotech partnered with Takeda, Lilly
|
|
Sep 6
|
12 Best Healthcare ETFs To Buy
|
|
Sep 6
|
Gilead Sciences: How One School Has Transformed Education for First-Generation Students
|
|
Sep 5
|
Gilead aims for 2026 opening for new cancer research center
|
|
Aug 4
|
Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030
|
|
Aug 4
|
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
|
|
Aug 4
|
Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis
|
|
Aug 4
|
Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript
|
|
Aug 3
|
Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Aug 3
|
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
|
|
Aug 3
|
UPDATE 1-Gilead quarterly profit falls on COVID sales drop, legal settlement charge
|
|
Aug 3
|
Gilead Sciences Cuts Profit Forecast on Legal Settlement
|
|
Aug 3
|
Gilead quarterly profit falls on COVID sales drop, legal settlement charge
|
|
Aug 3
|
Gilead Sciences Announces Second Quarter 2023 Financial Results
|
|
Aug 2
|
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
|
|
Aug 1
|
With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing
|
|
Jul 21
|
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
|
|
Jul 20
|
Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
|
|
Jul 20
|
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
|
|
Jul 20
|
A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity
|